Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"

Clin Pharmacol Ther. 2021 Nov;110(5):1164. doi: 10.1002/cpt.2372. Epub 2021 Aug 13.

Stefanie L Groenland¹, Dieuwertje R Geel², Jos H Beijnen^{2

3}, Egbert F Smit⁴, Alwin D R Huitema^{2

5}, Neeltje Steeghs¹

¹ Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
⁴ Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

No abstract available

Publication types